kaospilot & other

Predicting Injury Of Military Personnel And Athletes

2008-09-06T18:12:00.001-07:00

div

Latest News For Medical Devices / Diagnostics
Schools And Colleges Invent Healthcare Products For 'Siemens Healthcare Challenge'
21 Aug 2008

New 'Catch-And-Tell' Molecules Designed By Queen's Chemist
21 Aug 2008

Predicting Injury Of Military Personnel And Athletes
21 Aug 2008

View more news...

Today's Featured Health Videos

more videos ar available in our wellness videos section.

Most Popular Categories

cancer �
cardiovascular �
dermatology �
hiv �
nutrition �

diabetes �
obesity �
pediatrics �
psychology �
neurology �
alcohol �

urology �
breast cancer �
women's health �
infectious diseases �
respiratory �
sexual health �

gastrointestinal �
pain �
pregnancy �
bones �
medical devices �
medicare �

depression �
prostate �
smoking �
alzheimer's �
allergy �
sleep �

biology �
genetics �
eye health �
sports medicine �
hypertension �
abortion �

health insurance �
autism �
stem cell research �
adhd �
liver disease �
multiple sclerosis �

arthritis �
pharma industry �
seniors �
dentistry �
it �
nursing �

blood �
fertility �

More info

Bayer HealthCare And Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement In Vision Over 52 Weeks In A Phase 2

2008-08-27T18:16:00.001-07:00

�Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) proclaimed that patients with wet age-related macular degeneration (AMD) receiving VEGF Trap-Eye in a Phase 2 reference study on a PRN (as needful) dosing schedule continued to show highly significant improvements at 52 weeks in the primary and key secondary endpoints of retinal thickness (an anatomic measuring stick of treatment effect) and vision reach. The 12-week primary terminus results from the fixed-dosing period of the study were presented at the 2007 Retina Society conference in September 2007. The 32-week results of the Phase 2 study were presented at the 2008 Association for Research in Vision and Ophthalmology (ARVO) meeting in Fort Lauderdale, Florida. A full analysis of the 52-week results of the Phase 2 study will be presented at the 2008 meeting of the Retina Society on September 26-28, 2008 in Scottsdale, Arizona.

In this double-masked, prospective, randomized, multi-center Phase 2 trial, 157 patients were randomized to five dosage groups and treated with VEGF Trap-Eye in one eye. Two groups initially received monthly doses of 0.5 or 2.0 milligrams (mg) of VEGF Trap-Eye (at weeks 0, 4, 8, and 12) and three groups received quarterly doses of 0.5, 2.0, or 4.0 mg of VEGF Trap-Eye (at baseline and week 12). Following the initial 12-week fixed-dosing phase angle of the trial, patients continued to receive therapy at the same zen on a PRN dosing schedule based upon the physician judgement of the need for re-treatment in accordance with pre-specified criteria. Patients were monitored for safety, retinal thickness, and visual sharp-sightedness. These data represent the final annual analysis from the 52-week study.

Patients receiving four monthly doses of VEGF Trap-Eye, either 2.0 or 0.5 mg, for 12 weeks followed by PRN dosing thereafter, achieved mean improvements in visual acuity versus baseline of 9.0 letters (p

For all dosage cohorts combined, there was a 5.3 mean letter gather in visual acuity versus baseline at the calendar week 52 evaluation visit (p

VEGF Trap-Eye was generally well tolerated and there were no drug-related serious adverse events. There was i reported case of culture-negative endophthalmitis/uveitis in the work eye and one arterial thrombotic consequence, neither of which was deemed to be drug-related. The well-nigh common adverse events were those typically associated with intravitreal injections.

"The 52-week results underline that VEGF Trap-Eye has the potential to significantly
reduce retinal heaviness and meliorate vision," aforementioned Dr. Kemal Malik, fellow member of the Bayer HealthCare Executive Committee responsible for product development. "The further development of this compound is important for millions of people worldwide wHO suffer from this devastating ocular disease."

"Based upon retinene physicians' feedback, there remains a significant unmet medical need for a intervention for wet AMD that can faithfully improve ocular acuity over time without the need for monthly intravitreal injections," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "We are excited about these study findings and the potential for VEGF Trap-Eye to fulfil this demand pending the results of our on-going Phase 3 clinical studies."

About the Phase 3 Program in Wet AMD

Regeneron and Bayer HealthCare initiated a Phase 3 global development program for VEGF Trap-Eye in wet AMD in August 2007. In two Phase 3 trials VIEW 1 and VIEW 2 (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet age related macular degeneration), the companies are evaluating VEGF Trap-Eye dosed 0.5 mg every 4 weeks, 2 mg every 4 weeks, or 2 mg every 8 weeks (following three monthly doses) in direct comparison with ranibizumab (Lucentis�, a registered trademark of Genentech, Inc.) administered 0.5 mg every four-spot weeks according to its U.S. label during the first year of the studies. PRN dosing will be evaluated during the second year of each study. The VIEW1 cogitation (http://www.regeneron.com/vegftrap_eye.html) is currently enrolling patients in the United States and Canada and the VIEW2 study (hypertext transfer protocol://www.view2study.com) is currently enrolling patients in Europe, Asia Pacific, Japan, and Latin America. The companies ar collaborating on the worldwide development of VEGF Trap-Eye for the treatment of wet AMD, diabetic centre diseases, and other eye diseases and disorders. Bayer HealthCare volition market VEGF Trap-Eye external the United States, where the companies will share equally in profits from any future sales of VEGF Trap-Eye. Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

About VEGF Trap-Eye

Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body whose normal role is to initiation formation of new blood vessels (angiogenesis) to support the growth of the body's tissues and organs. It has also been associated with the abnormal growth and fragility of new blood vessels in the oculus, which lead to the development of wet AMD. The VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF). VEGF Trap-Eye is a specific and highly potent blocker of these growth factors. Blockade of VEGF, which tin can prevent abnormal blood vessel formation and vascular leak, has proved beneficial in the treatment of stiff AMD.

About Wet AMD

Age-related Macular Degeneration (AMD) is a prima cause of acquired blindness. Macular degeneration is diagnosed as either dry (nonexudative) or wet (exudative). In wet AMD, new roue vessels develop beneath the retina and leak blood and fluid. This escape causes disruption and disfunction of the retina creating blind muscae volitantes in central vision, and it can account for blindness in wet AMD patients. Wet AMD is the ahead cause of blindness for people over the eld of 65 in the U.S. and Europe.

About Bayer

The Bayer Group is a globular enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovational companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the diagnose Bayer Schering Pharma AG. Bayer HealthCare's aim is to find and manufacture products that will improve human and animal health worldwide. Find more entropy at http://www.bayerhealthcare.com.

About Bayer Schering Pharma

Bayer Schering Pharma is a worldwide in the lead specialty pharmaceutic company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a donation to medical progress and strives to improve the quality of life. Find more selective information at http://www.bayerscheringpharma.de.

Forward looking statements

This release crataegus laevigata contain advanced statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or operation of the company and the estimates n here. These factors include those discussed in Bayer's public reports which are available on the Bayer web site at world Wide Web.bayer.com. The troupe assumes no liability any to update these innovative statements or to conform them to future events or developments.

View drug information on Lucentis.

More info

Mp3 music: Rod Piazza

2008-08-17T18:19:00.001-07:00

Artist: Rod Piazza: mp3 download

   Genre(s):

Blues
R&B: Soul

Rod Piazza's discography:



Thrill Ville

   Year: 2007

Tracks: 14


For the Chosen Who

   Year: 2005

Tracks: 12


Vintage Live: 1975

   Year: 1998

Tracks: 10


Tough And Tender

   Year: 1997

Tracks: 1

A California-based megrims bandleader, harp player, and isaac Merrit Singer, Rod Piazza's stratospheric mouth harp wailings owe a heavy debt to both Little Walter and George "Mouth harp" Smith. Piazza began his professional career as a member of the Dirty Blues Band in the mid-'60s. The Dirty Blues Band recorded two albums for ABC/Bluesway -- an eponymic debut in 1967 and 1968's Stone Dirty. Piazza left field the

DVD Reviews - July 29

2008-08-07T20:21:00.001-07:00

The Band�s Visit
Director: Eran Kolirin
Stars: Ahuva Keren, Ronit Elkabetz, Sasson Gabai, and Khalifa Natour
Rating: PG-13

The Band�s Visit, the charming film about a touring Egyptian police orchestra that winds up disbursal a night in the wrong Israeli town, begins with a humble disclaimer: �Not many remember this. It was not that important.�

It�s a perfect summary of exactly why writer-director Eran Kolirin�s fairy fib works so well. There is no air of importance here. There is no attack to manufacture Middle East peace. A group of Arabs cannot transform an Israeli townspeople overnight. But what if a few Israelis and a few Arabs could achieve a glimmer of understanding between them? It makes for an about believable pansy tale. There is chemistry among the three leads: The starchy police colonel and band conductor Tawfiq (Sasson Gabai), the younger, less pent-up violinist Haled (Saleh Bakri) and the Israeli restaurant owner Dina (a mesmerizing Ronit Elkabetz, who appears to experience escaped from an Almodovar film).

For a movie about an orchestra, there�s an awful lot of muteness in The Band�s Visit, and it�s used to beautiful effect, subtly underscoring cultural differences, such as the way Tawfiq�s eyes can�t help but

Treat

2008-07-01T05:24:00.000-07:00

Artist: Treat

   Genre(s):
Metal: Heavy

Discography:


Dreamhunter

   Year: 1987
Tracks: 11


The Pleasure Principle

   Year: 1986
Tracks: 11


Scratch And Bite

   Year: 1985
Tracks: 9

Lil Wayne's new CD sells 423,000 in a day

2008-06-22T01:56:00.001-07:00

NEW YORK - The excessive leaks and bootlegging of Lil Wayne’s new album haven’t prevented it from being a hot seller: The rapper’s "Tha Carter III" sold 423,000 copies in its first day of release, according to Billboard magazine, citing figures from Nielsen SoundScan.
With such sales, Lil Wayne is on pace to sell about 900,000 copies of the CD in its first week and post the best sales debut of the year. Last year’s first-week top-seller was from Kanye West, who sold some 957,000 copies of "Graduation."
Though Lil Wayne has been on the rap scene for years, "Tha Carter III," released Tuesday, was expected to be the album that catapults the critically acclaimed rapper into pop superstardom. Ubiquitous on mixtapes and a frequent collaborator, he has owned the No. 1 spot on Billboard’s Hot 100 pop chart for the past few weeks with his song "Lollipop," and "Tha Carter III" is among this year’s most anticipated CDs.

His last two albums, "Tha Carter" and "Tha Carter II," sold 1.1 million and 1.4 million copies, respectively.
The release date for "Tha Carter III" was pushed back several times because the album was frequently leaked and bootlegged.
The year’s best first-week seller so far was posted by Mariah Carey. Her "EMC2" sold about 463,000 in the first week, according to Nielsen SoundScan.

Vinnie Moore

2008-06-21T16:20:00.000-07:00

Artist: Vinnie Moore

   Genre(s):
Rock
   Instrumental

Discography:


The Maze

   Year: 1999
Tracks: 10


Mind's Eye

   Year: 1990
Tracks: 9


Time Odyssey

   Year: 1988
Tracks: 10

Vinnie Moore is one of the most influencial and significant guitarists to emerge out of the virtuoso boom in the mid to recent eighties. Boasting six-spot studio apartment albums as of 2001, he is one of the almost placeable artists on the Shrapnel criminal record tag.

Showtime his life history at the untoughened eld of 12, Moore played clubs and parallel bars until Shrapnel bad wig Mike Varney discovered him through a magazine article. His connection with Varney light-emitting diode to a Pepsi commercial in 1985, which gave him enough realisation to record his first solo album, Minds Eye. His debut light-emitting diode to several awards from guitar magazines and sold o'er 100,000 copies, delivery him straight into the spotlight of the guitar domain.

The virtuoso craze of the former mid-eighties lED to more than well received releases on Shrapnel, and presently he began to do with other bands in the voiceless rock view. He joined Alice Cooper's stria for a go and the Hey Stoopid album, and released deuce selfsame popular instructional videos on performing guitar.

He secured a enlistment with Rush for his solo material, then off around and had a guitar clinic enlistment that spanned several continents. His dedication to teaching his craft has brought him much praise in musician's circles. Although the nineties saw a slump in the popularity of solo guitar music, Moore survived the downward vogue ascribable to his popular guitar clinics and lineament guitar acting.

Standing marvellous with fellow guitar heroes Al DiMeola and Joe Satriani, Vinnie Moore has enjoyed a successful working family relationship with Shrapnel records that has continued past the nineties into the future c. Despite never fracture the mainstream, Moore still has enjoyed a long and creatively comforting life history in the domain of instrumental guitar.

Moby Feat. Debbie Harry

2008-06-20T22:29:00.001-07:00

Artist: Moby Feat. Debbie Harry

   Genre(s):
Other

Discography:

New York New York

Year:
Tracks: 10

Charlie Mariano (Carnataka)

2008-06-20T22:22:00.000-07:00

Artist: Charlie Mariano (Carnataka)

   Genre(s):
Jazz

Discography:

Bangalore

Year:
Tracks: 8

Entertainment blog - news about music and movies

Paul Newman - Newman Doing Nicely Says Rep

2008-06-20T22:15:00.001-07:00

LATEST: Movie veteran PAUL NEWMAN has been forced to issue a statement after speculation about his failing health reached new highs - with reports suggesting he's battling lung cancer.

Tabloid stories earlier this year (08) suggested the beloved star and humanitarian had just six months to live and was under hospital supervision, but the actor laughed off the rumours, insisting his medical crisis was nothing more than treatment of athlete's foot and "hair loss".

And fears for the star's health were further heightened after lifestyle guru Martha Stewart posted a recent photograph of herself and Newman on her website earlier this week (begs02Jun08), which showed the actor appearing frail and in ill health.

Now, the star's representative Jeff Sanderson has contacted the media to ease the mounting concern over the actor's wellbeing, insisting Newman is "doing nicely".

Sanderson told reporters on Tuesday (10Jun08) he had been instructed to pass on the message by Newman himself, but declined to elaborate on specific details of Newman's current health situation.

On Monday (09Jun08), the Los Angeles Times reported the 83-year-old has reportedly been diagnosed with "terminal lung cancer" at New York's Sloan-Kettering Center, where Newman is currently receiving outpatient treatment.

A spokesperson for the hospital said they had no information about whether Newman was a patient there, according to online reports.

See Also

The Game - The Game To Quit Rap

2008-06-20T22:13:00.001-07:00

Rapper THE GAME's new release will be his last - because he wants to dedicate more time to family matters.

The Dreams hitmaker admits he's had enough of life on the road and wants to settle down and be a good dad.

He says, "I've been around for about six years and my kids are getting bigger and sometimes I'm gone for a long time, so I feel like a deadbeat dad.

"I know what I'm doing (is) securing their future financially but I miss the time that I get to spend with them."

And the rap star reveals his recent legal troubles helped him make up his idea to quit the rap business.

He explains, "The good thing about that is it kept me in California and I got to take my kids to karate class and tutoring and basketball games; I fell in love with being a father."

See Also

Kaipa

2008-06-20T22:12:00.002-07:00

Artist: Kaipa

   Genre(s):
Rock: Progressive

Discography:

Notes From The Past

Year: 2002
Tracks: 11

Before the seeds of the Flower Kings were planted, Kings' guitarist/vocalist Roine Stolt was working in the band Kaipa. The isthmus was originally formed under the name Ura Kaipa by Hans Lundin (keys) and Tomas Eriksson (bass) in 1973. The duo had worked together previously in San Micheals and for this project recruited Thomas Sjoberg on drums. Illness forced Sjoberg to leave behind the group the following year, though. His successor was Ingemar Bergman. Stolt linked the band in 1974 besides, shortly later on they had cut the "Ura" from the name of the ring. Their self-titled debut handout, with a cover adorned by a ikon painted by Stolt, was released the following class. Their sophomore oblation, Inget Nytt Under Solen, was recorded and released in 1976. Late in 1977, Eriksson left the band, merely that was surely non to be the last lineup variety for the year. Indeed, the group chose to add a leash singer in the personage of Mats Lofgren. They besides replaced Ericksson with Mats Lindberg before the class was over. Their succeeding disk was 1978's Solo.

By this peak, forces were working to pull the ring apart, and in 1979 Stolt left the group. His successor was Max Ahman. This lineup of the band recorded their following record album, Hander, late in 1979 for a 1980 handout. Throughout 1980, the group went through many problems, though. First they added Torkel Thyrell on bass, just the lineup suffered a serious blow when Lofgren left the group. His successor came in the form of a female, Anne Chaaban. However, neither of the deuce raw recruits was to remain with the mathematical group past November of that same class. In an unusual turn of events, the group recruited Mats Lindberg to supplant Thyrell. However, this Lindberg only bore the same appoint as their premature bassist, only was not the like adult male. Before 1981 was through, Bergman would leave behind the group. So, Kaipa was looking for a new drummer. They establish the substitute in Pelle Andersson. That grouping released the album Nattdjurstid late in 1982. It would rise to be the last for a retentive time. In fact, the band distinct to consider a break up from all the strong shape, simply that smash selfsame nigh became a permanent unmatchable. They would not operate together again until the year 2001 when they re-formed to platter their Notes From the Past album. That record (released in 2002) featured a lineup composed of Lundin, Stolt, Morgan Agren, Patrik LundstrÃ¶m, and Jonas Reingold (world Health Organization Stolt industrial plant with in the Flower Kings).

Aiko

2008-06-20T22:12:00.001-07:00

Artist: Aiko

   Genre(s):
Other

Discography:

Sakura No Ki No Shita

Year: 2000
Tracks: 11

"Vertigo" is still a dizzying, dazzling display of moviemaking, 50 years later

kaospilot

2008-06-20T22:08:00.000-07:00

Artist: kaospilot

   Genre(s):
Rock

Discography:


For your safety

   Year: 2002
Tracks: 6


Self Titled

   Year:
Tracks: 11